S
SNDX
Syndax Pharmaceuticals, Inc. Common Stock
$13.53
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Syndax Pharmaceuticals, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$2.52
P/E
—
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.48
Oct 29
Posts
No posts about SNDX yet.
About Syndax Pharmaceuticals, Inc. Common Stock
Syndax Pharmaceuticals is a biotechnology company that develops cancer and immune-system drugs. Its main product is Niktimvo (axatilimab), approved in the US for chronic graft-versus-host disease. That is a serious complication in which donated cells from a bone marrow transplant attack the patient's own body. Syndax earns money from sales of Niktimvo, which it shares with its partner Incyte.